
Opinion|Videos|March 31, 2025
KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025
Experts discuss the KEYMAKER-U03 trial, highlighting lenvatinib plus belzutifan as a promising option in advanced renal cell carcinoma and new directions emerging from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC
2
Zanzalintinib/Atezolizumab Misses Survival End Point in Non-MSI-H mCRC Subgroup
3
Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial
4
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
5



















































































